About Biolexis Therapeutics
Biolexis Therapeutics is a private company based in Lehi, Utah, incorporated in 2021 in Delaware. It has reported $6,325,000 raised in five offerings on Form D since March 2022.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| May 20, 2026 | Jun 3, 2026 | $1,600,000of $12.0M target | 2 | $800K | Convertible Promissory NotesRule 506(b) | Form D ↗ |
| Oct 3, 2023 | Oct 17, 2023 | $1,000,000target not set | 1 | $1.0M | EquityRule 506(b) | Form D ↗ |
| Sep 19, 2023 | Oct 3, 2023 | $725,000fully sold | 6 | $120K | EquityRule 506(b) | Form D ↗ |
| Aug 18, 2022 | Sep 2, 2022 | $1,500,000target not set | 2 | $750K | EquityRule 506(b) | Form D ↗ |
| Feb 3, 2022 | Mar 1, 2022 | $1,500,000of $2.0M target | 17 | $88,235 | Debt, Convertible Promissory NotesRule 506(b) | Form D ↗ |
| Total, five offerings | $6,325,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Biolexis Therapeutics's Form D filed Jun 3, 2026.
JC
AS
Anthony Steve
Director
David Bearss
Co-founder · Chairman
Also a director at Canary Speech and Reglagene and a chief executive officer and director at Halia Therapeutics.
Earlier filings also listed Dr. Hariprasad Vankayalapati (executive officer and director, last listed Oct 2023), Dr. David Bearss (executive officer and director, last listed Oct 2023) and David Taylor (cfo and director, last listed Oct 2023).